Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: analysis from phase 2 and 3 clinical trials

Axel Hauschild*, Paolo A. Ascierto, Dirk Schadendorf, Jean Jacques Grob, Antoni Ribas, Felix Kiecker, Caroline Dutriaux, Lev V. Demidov, Céleste Lebbé, Piotr Rutkowski, Christian U. Blank, Ralf Gutzmer, Michael Millward, Richard Kefford, Tomas Haas, Anthony D'Amelio, Eduard Gasal, Bijoyesh Mookerjee, Paul B. Chapman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

29 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: analysis from phase 2 and 3 clinical trials'. Together they form a unique fingerprint.

Medicine & Life Sciences